SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is trending following the FDA approval of YARTEMLEA, making it the first and only approved therapy for the life-threatening transplant-associated thrombotic microangiopathy (TA-TMA). The community is celebrating this significant milestone, with discussions centered on the stock's perceived undervaluation, potential for a short squeeze, and heightened speculation around a buyout, especially given a prior licensing deal with Novo Nordisk.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Biohaven Pharmaceutical Holding Company Ltd

Biohaven is trending following a recent clinical trial failure for its depression drug, a development released during a holiday period that drew community criticism for its timing. However, investor attention is quickly shifting to the company's robust pipeline, particularly upcoming data for its epilepsy, obesity, and oncology programs. Significant insider buying after a recent offering has also fueled renewed confidence, signaling a belief in future growth despite prior regulatory setbacks.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax (DVAX) is trending due to the announcement that Sanofi will acquire the company for cash, a strategic move to bolster its adult immunization portfolio with DVAX's Hepatitis B vaccine, Heplisav-B, and a shingles candidate. The community is actively debating the acquisition price, with many long-term holders expressing disappointment and questioning if the company was undersold, while some speculate about potential counter-offers. This acquisition reflects ongoing consolidation in the biotech vaccine sector, integrating DVAX's assets into a larger pharmaceutical framework.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is a trending topic after reporting robust earnings, showcasing a critical milestone with its first positive adjusted EBITDA, coupled with increased revenue guidance that signals continued growth in AI-driven precision medicine. Despite these strong results and several analyst upgrades, the community is actively debating recent price volatility, with many expressing long-term conviction in the company's AI-driven healthcare platform while others point to "sell the news" dynamics and market manipulation.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu (SHIB) is trending with highly polarized community sentiment as investors debate its immediate future. Many loyal holders view recent price action as a prime accumulation opportunity, anticipating a strong rally, while a vocal contingent labels it a "scam" or "shitcoin" and questions its underlying value. This prominent meme coin continues to generate significant conversation regarding its potential amidst broader market volatility.

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Spruce Biosciences Inc

Spruce Biosciences is trending following the FDA's Breakthrough Therapy Designation for its rare neurological disease therapy and recent analyst upgrades. This major catalyst has sparked intense community debate, with bulls anticipating further upside due to its low float and potential acquisition interest, while others express concern over recent dilution from a private placement and its small target patient population.

Aduro Clean Technologies, Inc. engages in the manufacture of oils and specialty chemicals using waste plastics. It focuses on hydrochemolytic technology to transform post-consumer polymer waste into a resource for the circular economy. It also develops a novel chemical conversion process to transform waste plastics and low grade renewable oils into renewable fuels and specialty chemicals. The company was founded on January 10, 2018 by Ofer Vicus and William Marcus Trygstad and is headquartered in Sarnia, Canada.

Aduro Clean Technologies Inc

Aduro Clean Technologies is trending as recent developments, including the closure of a public offering and significant technical validations like graduating Shell's GameChanger program and successful steam-cracking trials, energize investors. Community discussion highlights the company's de-risking milestones and vast market potential for its Hydrochemolytic technology, though skeptics continue to challenge its economic viability and commercial pathway.

Babcock & Wilcox Enterprises, Inc. engages in the provision of fossil and renewable power generation and environmental equipment. It operates through the following segments: B&W Renewable, B&W Environmental, and B&W Thermal. The B&W Renewable segment supports a circular economy, diverting waste from landfills to use for power generation and replacing fossil fuels, while recovering metals and reducing emissions. The B&W Environmental segment focuses on systems for cooling, ash handling, particulate control, nitrogen oxides and sulfur dioxides removal, chemical looping for carbon control, and mercury control. The B&W Thermal segment offers steam generation equipment, aftermarket parts, construction, maintenance, and field services for plants in the power generation, oil and gas, and industrial sectors. The company was founded by George H. Babcock, Stephen Wilcox, Jr., and Joseph P. Manton in 1856 and is headquartered in Akron, OH.

Babcock & Wilcox Enterprises Inc

Babcock & Wilcox is trending due to recent significant contract announcements, highlighted by a $1.5 billion notice to proceed with Applied Digital for AI data center power, alongside new carbon capture and refinery projects. The community views BW as a critical player in the burgeoning AI energy infrastructure, with ongoing discussions around its long-term growth potential. While many are optimistic about the strategic pivot and debt reduction, some express caution regarding contract finalization timelines, potential share dilution, and the broader sector's valuation.

The Cosmos network consists of many independent, parallel blockchains, called zones, each powered by classical Byzantine fault-tolerant (BFT) consensus protocols like Tendermint. Some zones act as hubs with respect to other zones, allowing many zones to interoperate through a shared hub. The architecture uses classic BFT and Proof-of-Stake algorithms, instead of Proof-of-Work. Cosmos can interoperate with multiple other applications and cryptocurrencies, something other blockchains can’t do well. By creating a new zone, you can plug any blockchain system into the Cosmos hub and pass tokens back and forth between those zones, without the need for an intermediary.  While the Cosmos Hub is a multi-asset distributed ledger, there is a special native token called the atom. ATOM have three use cases: as a spam-prevention mechanism, as staking tokens, and as a voting mechanism in governance.  As a spam prevention mechanism, ATOM are used to pay fees. The fee may be proportional to the amount of computation required by the transaction, similar to Ethereum’s concept of “gas”. Fee distribution is done in-protocol and a protocol specification is described here.  As staking tokens, ATOM can be “bonded” in order to earn block rewards. The economic security of the Cosmos Hub is a function of the amount of ATOM staked. The more ATOM that are collateralized, the more “skin” there is at stake and the higher the cost of attacking the network. Thus, the more ATOM there are bonded, the greater the economic security of the network.  Atom holders may govern the Cosmos Hub by voting on proposals with their staked ATOM.

Cosmos

ATOM is trending as community discussion intensifies around its 'Internet of Blockchains' model versus emerging, compliance-first infrastructure like Keeta, which boasts high throughput for institutional finance. Many holders are debating ATOM's long-term value and recent price stagnation, even as a significant tokenomics redesign aims to shift towards a revenue-based model, highlighting a broader market focus on both foundational interoperability and specialized, high-performance settlement layers.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himax Technologies is a hot topic as its Wafer-Level Optics technology is critical for Co-Packaged Optics (CPO) and TSMC's COUPE platform, essential for next-gen AI data centers. The community is buzzing about the potential for substantial revenue growth, with many anticipating a significant ramp-up in 2026 as this technology addresses the intense bandwidth and power demands of AI. This positions Himax as a key enabler for leading AI chipmakers like NVIDIA and AMD.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CureVac (NASDAQ:CVAC) Reaches New 12-Month High - Should You Buy?

CureVac (NASDAQ:CVAC) Reaches New 12-Month High - Still a Buy...

CureVac (NASDAQ:CVAC) Hits New 12-Month Low - Here's Why

CureVac (NASDAQ:CVAC) Hits New 12-Month Low - Should You Sell...

CureVac (NASDAQ:CVAC) Shares Gap Down - Time to Sell?

CureVac (NASDAQ:CVAC) Shares Gap Down - Time to Sell...

CureVac (NASDAQ:CVAC) Trading Down 9.9% - Time to Sell?

CureVac (NASDAQ:CVAC) Shares Down 9.9% - Here's Why...

CureVac N.V. (NASDAQ:CVAC) Receives Average Recommendation of "Hold" from Analysts

CureVac N.V. (NASDAQ:CVAC - Get Free Report) has been assigned a consensus recommendation of "Hold" from the six research firms that are presently covering the stock, MarketBeat Ratings reports. One...

CureVac Enters Oversold Territory (CVAC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a...

Carlson Capital L.P. Makes New Investment in CureVac N.V. $CVAC

Carlson Capital L.P. bought a new position in CureVac N.V. (NASDAQ:CVAC - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange...

CureVac (NASDAQ:CVAC) Sees Large Volume Increase - Here's What Happened

CureVac (NASDAQ:CVAC) Sees Large Volume Increase - Still a Buy...

Company News for Nov 25, 2025

Companies In The News Are: CVAC, CAAP, NVO, BABA.

CureVac N.V. (NASDAQ:CVAC) Given Consensus Rating of "Hold" by Brokerages

Shares of CureVac N.V. (NASDAQ:CVAC - Get Free Report) have been given an average rating of "Hold" by the six analysts that are presently covering the stock, MarketBeat.com reports. Five research...

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.10	--	--	N/A
Q3 '25	-$0.08	--	--	N/A
Q2 '25	-$0.21	-$0.24	-13.77%	MISSED
Q1 '25	-$0.24	--	--	N/A
Q4 '24	-$0.22	--	--	N/A

CVAC
CureVac N.V.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest CVAC News

CVACCureVac N.V.